Thrombopoietin Receptor
Thrombopoietin (a.k.a megakaryocyte growth and development factor) receptor plays a role in megakaryocyte, platelet formation and TPO-R-dependent immune responses.
Products Related to Thrombopoietin Receptor(7)
- GC12513EltrombopagCAS: 496775-61-2Purity: >99.00%
Eltrombopag is a non-peptide thrombopoietin receptor (TPO-R) specific agonist with an EC₅₀ of 0.19μM for TPO-R.
- GC16341Eltrombopag OlamineCAS: 496775-62-3Purity: >98.00%
A thrombopoietin receptor agonist and iron chelator
- GC31669Lusutrombopag (S-888711)CAS: 1110766-97-6Purity: >98.00%
Lusutrombopag, an orally bioavailable, small molecule thrombopoietin receptor agonist, is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- GC31670Avatrombopag (AKR-501)CAS: 570406-98-3Purity: >98%
Avatrombopag (AKR-501) (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM).
- GC32450TPO agonist 1CAS: 1033040-23-1Purity: >98.00%
TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic.
- GC62407(E/Z)-Eltrombopag 13CCAS: 1217230-31-3Purity: >98.00%
(E/Z)-Eltrombopag 13C ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled.
- GC69221HetrombopagCAS: 2114365-78-3Purity: >98%
Hetrombopag is an effective thrombopoietin receptor agonist. It is both effective and well-tolerated, with controllable safety. Hetrombopag has the potential for research in immune thrombocytopenia.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC12513 | Eltrombopag | 496775-61-2 | >99.00% | |
Eltrombopag is a non-peptide thrombopoietin receptor (TPO-R) specific agonist with an EC₅₀ of 0.19μM for TPO-R. | ||||
| GC16341 | Eltrombopag Olamine | 496775-62-3 | >98.00% | |
A thrombopoietin receptor agonist and iron chelator | ||||
| GC31669 | Lusutrombopag (S-888711) | 1110766-97-6 | >98.00% | |
Lusutrombopag, an orally bioavailable, small molecule thrombopoietin receptor agonist, is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. | ||||
| GC31670 | Avatrombopag (AKR-501) | 570406-98-3 | >98% | |
Avatrombopag (AKR-501) (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). | ||||
| GC32450 | TPO agonist 1 | 1033040-23-1 | >98.00% | |
TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. | ||||
| GC62407 | (E/Z)-Eltrombopag 13C | 1217230-31-3 | >98.00% | |
(E/Z)-Eltrombopag 13C ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. | ||||
| GC69221 | Hetrombopag | 2114365-78-3 | >98% | |
Hetrombopag is an effective thrombopoietin receptor agonist. It is both effective and well-tolerated, with controllable safety. Hetrombopag has the potential for research in immune thrombocytopenia. | ||||
